NCT02922959

Brief Summary

This project will further develop and test the Tailored Telephone Intervention delivered by Peers to Prevent Recurring Opioid Overdoses (TTIP-PRO), a promising, low-cost, intervention to facilitate entry into medication assisted treatment (MAT) for individuals experiencing a non-fatal opioid overdoses (OOD). A prior small-scale pilot/feasibility study of TTIP-PRO (NCT02282306) found that the participating patients and the Peer Interventionists were satisfied with their participation, the intervention was acceptable, and the system for generating patient-tailored intervention information performed well. The overall goal of the present study is to conduct a pilot randomized controlled trial of TTIP-PRO versus a control group. It is hypothesized that patients in the TTIP-PRO group will have more favorable drug-abuse-related outcomes than patients in the control group.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Feb 2017

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 30, 2016

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 4, 2016

Completed
4 months until next milestone

Study Start

First participant enrolled

February 7, 2017

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 25, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 25, 2019

Completed
11 months until next milestone

Results Posted

Study results publicly available

June 24, 2020

Completed
Last Updated

June 24, 2020

Status Verified

June 1, 2020

Enrollment Period

2.5 years

First QC Date

September 30, 2016

Results QC Date

June 4, 2020

Last Update Submit

June 4, 2020

Conditions

Keywords

Opioid Substitution TreatmentTelephone interventionsecondary preventionnaloxone

Outcome Measures

Primary Outcomes (1)

  • Medication-Assisted Treatment Enrollment

    whether or not participant enrolled in medication-assisted treatment within the follow-up period

    12 months

Secondary Outcomes (3)

  • Opioid Overdose Experience

    12 months

  • Change in Opioid Use (Timeline Follow-back)

    at 12-month visit

  • Change in Opioid Use (Urine Drug Screen)

    at 12-month visit

Study Arms (2)

PTOEND

ACTIVE COMPARATOR

PTOEND: Personally-tailored opioid overdose prevention education and naloxone distribution. Participants in this arm will be given a NARCAN (naloxone) nasal spray kit and personally-tailored information packet about opioid overdose and treatment.

Drug: naloxone nasal spray kitBehavioral: Personally-tailored opioid overdose prevention education (information packet)

PTOEND+PI

EXPERIMENTAL

PTOEND+PI: Personally-tailored opioid overdose prevention education and naloxone distribution, plus Peer Intervention. In addition to a NARCAN (naloxone) nasal spray kit and personally-tailored information packet about opioid overdose and treatment, participants randomized to this arm will also receive the experimental Peer Intervention.

Behavioral: Peer InterventionDrug: naloxone nasal spray kitBehavioral: Personally-tailored opioid overdose prevention education (information packet)

Interventions

The Peer Intervention is a 20-minute telephone call delivered by a Peer Interventionist, who is trained to answer questions about the content of the personally-tailored information packets. The primary goal of the call is for the participant and the Peer Interventionist to have an open exchange of information about medication-assisted treatment (MAT) for opioid use disorder.

PTOEND+PI

Naloxone nasal spray (NARCAN) is a potentially life-saving medication that can stop or reverse the effects of an opioid overdose. This nasal spray is approved by the FDA for reversing OODs and has a favorable side-effects profile. A take-home kit will be provided to the patient participants, which may be useful in the event of a future opioid overdose.

Also known as: NARCAN
PTOENDPTOEND+PI

Personally-tailored information packet with three participant-specific reports ("Personal Overdose Risk Factors Report"; "Medication Assisted Treatment (MAT) Report"; and the "Opioid Overdose Information Report"), and general written information about opioid overdose and treatment for opioid use disorder.

PTOENDPTOEND+PI

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Report having been treated for an OOD within the past 6 months
  • Age 18 years or older;
  • Scores "high risk" for heroin and/or non-medical use of prescription opioids on the National Institute on Drug Abuse modified Alcohol, Smoking and Substance Involvement Screening Test (NIDA-modified ASSIST) (i.e., ≥ 27)
  • Be able to understand the study, and having understood, provide written informed consent in English
  • Access to a phone (for TTIP-PRO intervention and phone follow-up)
  • Be willing to have their intervention audio recorded and rated if randomized to TTIP-PRO
  • Have an opioid-positive baseline/screening urine drug screen.

You may not qualify if:

  • In the judgment of the investigator, would not be expected to complete the study protocol (e.g., due to relocation from the clinic area, probable incarceration, etc.)
  • Current engagement in addiction treatment
  • Residence more than 40 miles from the location of follow-up visits
  • Inability to provide sufficient contact information (must provide at least 2 reliable locators)
  • Prior participation in the current study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Cincinnati Addiction Sciences Division

Cincinnati, Ohio, 45229, United States

Location

Related Publications (1)

  • Kropp F, Wilder C, Theobald J, Lewis D, Winhusen TJ. The feasibility and safety of training patients in opioid treatment to serve as peer recovery support service interventionists. Subst Abus. 2022;43(1):527-530. doi: 10.1080/08897077.2021.1949667. Epub 2021 Jul 8.

MeSH Terms

Conditions

Drug OverdoseOpioid-Related DisordersSubstance-Related Disorders

Interventions

Naloxone

Condition Hierarchy (Ancestors)

Prescription Drug MisuseDrug MisuseChemically-Induced DisordersMental DisordersNarcotic-Related Disorders

Intervention Hierarchy (Ancestors)

MorphinansOpiate AlkaloidsAlkaloidsHeterocyclic CompoundsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic Compounds

Results Point of Contact

Title
Theresa Winhusen
Organization
University of Cincinnati Addiction Sciences Division

Study Officials

  • Theresa Winhusen, PhD

    University of Cincinnati

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor; Associate Vice Chair and Division Director of Addiction Sciences

Study Record Dates

First Submitted

September 30, 2016

First Posted

October 4, 2016

Study Start

February 7, 2017

Primary Completion

July 25, 2019

Study Completion

July 25, 2019

Last Updated

June 24, 2020

Results First Posted

June 24, 2020

Record last verified: 2020-06

Data Sharing

IPD Sharing
Will share

Data will be shared in a timely manner, i.e., no later than the acceptance for publication of the main findings from the final dataset. The dataset will include information about illegal activities (e.g., illicit opioid use, etc.). Thus, in addition to only a de-identified database being shared, we will also require a data sharing agreement. The data sharing agreement will require commitment to: 1) not re-disclose the data; 2) secure the data; 3) use the data for research purposes only; 4) make no attempt to identify individual participants; 5) destroy the data once the planned research activities have been completed; 6) follow all relevant NIH policies.

Locations